Average weight loss per week on Wegovy: what clinical trials actually found

What the STEP 1 numbers actually mean week by week

The STEP 1 trial, published in the New England Journal of Medicine, is the foundational evidence for Wegovy. Participants on semaglutide 2.4mg lost a mean of around 15% of body weight over 68 weeks, roughly 15.3 kg for someone starting at 100 kg. Divide that across 68 weeks and you get approximately 0.22 kg per week, and if you want a closer look at how that figure breaks down, our guide to average weekly weight loss on Wegovy walks through the numbers in detail. In practice, the weekly rate was not that steady. Early weeks, when the dose is still escalating through 0.25mg, 0.5mg and 1.0mg, tend to bring the sharpest initial changes. By the time a patient reaches and settles at 2.4mg, the weekly figure typically flattens. This is normal physiology: as the body adapts and appetite suppression becomes the new baseline, the rate of change moderates. Thinking about what three months on Wegovy typically looks like can help set expectations for that escalation window specifically.

It is worth being honest about what a weekly average conceals. Some people on the higher end of the STEP 1 results lost considerably more; the placebo-controlled data showed a range, not a single trajectory. The mean is a useful anchor, not a ceiling or a floor.

Why your weekly rate will differ from the trial average

Clinical trials recruit specific populations under controlled conditions. Real-world weekly weight loss on Wegovy varies for several practical reasons. Starting weight matters: someone beginning at 130 kg has more scope for early rapid change than someone starting at 85 kg, even if the eventual percentage loss is similar. Dose tolerability also plays a role, if nausea or other gastrointestinal effects lead a prescriber to slow the escalation schedule, the weekly rate in the first months will be different from someone who tolerated each step smoothly. Lifestyle changes running alongside treatment have a measurable effect too. The NHS guidance on semaglutide is clear that Wegovy is indicated alongside a reduced-calorie diet and increased physical activity, not instead of them. How carefully those are maintained influences how the medicine's appetite-suppressing action translates into actual scale movement each week. If you are curious about the longer arc of results, the broader evidence on total Wegovy weight loss sets the weekly picture inside the full treatment span.

The 7.2mg dose and what it changes about the pace

Since the MHRA approved a dedicated single-dose 7.2mg Wegovy pen in April 2026, the weekly-average picture has an update worth knowing about. Trial data for the higher dose reported around 20.7% average weight loss over 72 weeks, compared with roughly 15% at 2.4mg over a slightly shorter period. Arithmetically, that points to a modestly faster weekly pace at the higher dose, though the studies were not identical in design or duration so direct week-for-week comparison requires care. The 7.2mg pen is indicated for adults with a BMI of 30 or above; the titration still starts at 0.25mg and steps up over months under prescriber supervision, so the early weekly figures are similar regardless of the target maintenance dose. Specific dose availability is confirmed at consultation, the full Wegovy overview covers what the different doses mean practically.

Setting realistic expectations, and why weekly weigh-ins can mislead

It is completely understandable to want a weekly number: tracking progress feels more manageable when you have a concrete benchmark. The difficulty is that weekly scales data is noisy. Water retention, hormonal cycles, digestive patterns and the timing of a weigh-in relative to a meal can all shift the reading by 0.5–1.5 kg with no change in actual fat mass. Clinicians generally prefer to assess trend over four-week intervals rather than week to week. The average weekly weight loss figure from trials is most useful as a calibration tool, it tells you whether your four-to-eight week trajectory is broadly consistent with what the evidence would predict, not whether any single Tuesday morning weigh-in is on track. If you want to understand how individual results vary further, the range of outcomes people experience on Wegovy explores what sits above and below the mean. Those who found the weekly pace slower than expected in the first months often find the picture looks different at the six-month mark. A prescriber can review progress and adjust the plan, which is one reason checking your eligibility for a clinical consultation is the practical next step if you are considering starting treatment.